Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
Toni K. Choueiri, Bernard J. Escudier, Thomas B. Powles et al. · The Lancet Oncology · 2016
Cited by 958 works. doi:10.1016/s1470-2045(16)30107-3
Authors
- Toni K. Choueiri
- Bernard J. Escudier
- Thomas B. Powles
- Nizar M. Tannir
- Paul N. Mainwaring
- Brian I. Rini
- Hans J. Hammers
- Frede N. Donskov
- Bruce J. Roth
- Katriina Johanna Peltola
- Jae‐Lyun Lee
- Daniel Y.C. Heng
- Manuela Schmidinger
- Neeraj Agarwal
- Cora Nanette Sternberg
- David F. McDermott
- Dana T. Aftab
- Colin Hessel
- Christian Scheffold
- Gisela M. Schwab
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- EAU Guidelines on Renal Cell Carcinoma: 2014 Update
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial
- Phase 3 trial of everolimus for metastatic renal cell carcinoma
- Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma